Today: 1 July 2026
Browse Category

Pharmaceutical Industry 4 February 2026 - 16 April 2026

Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions

Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions

Shares of Hims & Hers Health surged Thursday after the FDA signaled it would review restrictions on certain peptides—a move that’s opened up a new narrative for investors as the telehealth firm shifts focus from promoting compounded GLP-1 drugs. By early afternoon in New York, the stock was changing hands at $26.65, up $2.36 on the day. Timing is crucial for Hims, which overhauled its U.S. weight-loss plan just last month. In March, the company cut out advertising for compounded GLP-1 offerings across its platform and all marketing channels, while at the same time moving to widen access to branded therapies via a deal with Novo Nordisk.
16 April 2026
···
Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus

Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus

Atara Biotherapeutics jumped roughly 18% late Monday morning, rallying alongside other rare-disease biotech stocks after word got out that the FDA’s head of biologics is set to depart next month. uniQure picked up about 15%, while Regenxbio climbed close to 20%. This is significant: Atara remains in pursuit of a U.S. route for EBVALLO, also known as tabelecleucel, a cell therapy targeting Epstein-Barr virus-positive post-transplant lymphoproliferative disease. The condition—rare, frequently deadly—can turn up after organ or stem-cell transplants, and, right now, there are no approved therapies for it in the U.S.
9 March 2026
····
Capricor Therapeutics Stock Rises Ahead of March 12 Update as FDA Watch on Duchenne Drug Builds

Capricor Therapeutics Stock Rises Ahead of March 12 Update as FDA Watch on Duchenne Drug Builds

Capricor Therapeutics jumped 7.6% to $30.01 early Monday after the company scheduled its fourth-quarter and full-year results for March 12, putting deramiocel—the company’s experimental treatment for Duchenne muscular dystrophy—back in focus. Duchenne is a genetic disorder that causes progressive muscle loss. Capricor plans to publish results after Thursday’s close and will hold its conference call at 4:30 p.m. ET. Timing is key here: Capricor is working to get U.S. approval back on track for deramiocel in Duchenne-related cardiomyopathy after the FDA rejected it in July. The company plans to showcase full Phase 3 results at the Muscular Dystrophy Association meeting on March 11, and as of February, said it had already submitted the complete HOPE-3 study report as part of its biologics license application, or BLA—the formal step for approval.
9 March 2026
·
Tango Therapeutics stock jumps 36% after Q4 results, Erasca cancer trial pact

Tango Therapeutics stock jumps 36% after Q4 results, Erasca cancer trial pact

Tango Therapeutics surged about 36% Thursday, propelled by fourth-quarter numbers and news of a fresh partnership with Erasca to study vopimetostat—the company’s lead drug—in pancreatic and lung cancer settings. Shares recently changed hands at $16.83. The update is significant for Tango, which has its sights set on advancing vopimetostat—a PRMT5 inhibitor targeting a cancer-linked enzyme—out of early-phase trials and into a pivotal study, the usual step toward seeking approval. Tango still plans to kick off the second-line pancreatic cancer trial in 2026, after initial treatment, and says first phase 1/2 combination data should arrive before year's end.
6 March 2026
···
FDA hits Novo Nordisk with another Ozempic ad warning — second strike in weeks

FDA hits Novo Nordisk with another Ozempic ad warning — second strike in weeks

Novo Nordisk A/S has been flagged again by the U.S. Food and Drug Administration, which says a consumer ad for its diabetes star, Ozempic, overstates the drug’s benefits and misleads viewers. It's the Danish company’s second warning about its advertising in less than a month. The change strikes at Novo’s core. Ozempic and Wegovy are central to the company’s U.S. ambitions, and marketing has been crucial as rivals crowd the space. Altering the pitch now runs the risk of muddling things further for patients and doctors already sorting through a tangle of options.
4 March 2026
·
Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play

Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play

New York, Feb 26, 2026, 08:43 EST — Premarket Hims & Hers Health shares nudged 0.3% higher ahead of Thursday’s open, building on Wednesday’s 2.3% advance. The telehealth firm wrapped up the last session at $15.82, after trading in a range from $15.06 to $16.46 during the day. On Tuesday, the stock had dropped to $13.74.
26 February 2026
···
Cigna stock jumps as earnings beat meets soft 2026 outlook and FTC insulin settlement

Cigna stock jumps as earnings beat meets soft 2026 outlook and FTC insulin settlement

New York, February 5, 2026, 11:03 EST — Regular session The Cigna Group’s shares jumped about 3.2% to $280.46 in late morning trading Thursday after it unveiled quarterly results and its 2026 outlook. UnitedHealth slipped nearly 1.6%, CVS Health rose close to 2.2%, and Elevance slipped around 0.7%. CI stock traded in a range from $270.00 up to $283.59.
5 February 2026
···
Veradermics IPO Pops Above Range as Eli Lilly Lines Up a 5% Stake Play

Veradermics IPO Pops Above Range as Eli Lilly Lines Up a 5% Stake Play

Veradermics, the biopharma working on an oral hair-loss treatment, set its IPO price at $17 a share, above the initial range, pulling in roughly $256.3 million. The stock is slated to start trading Wednesday on the New York Stock Exchange under the ticker “MANE.” The deal may be modest by Wall Street measures, but it arrives amid a shaky period for biotech IPOs. Pricing above the expected range indicates investors were ready to take a chance on a hair-loss treatment — even though the company remains in late-stage trials.
4 February 2026
···
Zurich’s £8bn Beazley bid jolts FTSE 100 to a fresh record as GSK rallies, AI fears hit data stocks

Zurich’s £8bn Beazley bid jolts FTSE 100 to a fresh record as GSK rallies, AI fears hit data stocks

Zurich Insurance Group has struck outline terms for an about 8 billion pound cash takeover of FTSE 100 underwriter Beazley, with Beazley saying it would be minded to recommend the offer if Zurich turns it into a firm bid by Feb. 16. The talks matter now because the UK Takeover Code forces a bidder into a near-term decision: Zurich must either publish a formal offer by a set deadline or step back. For Zurich, the prize is a deeper push into specialty insurance — cover for complex risks such as cyber, marine and aviation — and a bigger footprint through Lloyd’s of London.
4 February 2026
·····
1 2 3 4 … 9

Stock Market Today

  • Pacific Current Group Tells ASX About Progress on Buy-Back Plan
    June 30, 2026, 11:38 PM EDT. Pacific Current Group Ltd (ASX: PAC) gave an update to the Australian Securities Exchange (ASX) on its on-market share buy-back program. The company is buying back its shares on market. Pacific Current is aiming to boost shareholder value through capital management. The announcement may affect stock liquidity and price. Investors can watch ASX announcements for more detail on the buy-back.
Go toTop